The new findings shed light on how cancer cells found in different parts of a tumour behave differently.
A new kidney cancer drug combination of pembrolizumab with axitinib gets an initial no for the NHS in England
One kidney cancer treatment and two lung cancer drugs have been recommended for use on the NHS in Scotland.
A combination of immunotherapy drugs will be made available to NHS patients with advanced and aggressive kidney cancer on the NHS in England.
Combining a targeted cancer drug with an immunotherapy extends the lives of advanced kidney cancer patients, according to two clinical trials.
Women with bladder or kidney cancer may lose out on a prompt diagnosis if they are already being regularly treated for recurring urinary tract infections (UTIs)
Researchers have launched a clinical trial to develop a breath test, analysing molecules that could indicate the presence of cancer at an early stage.
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.
The targeted drug sunitinib is as effective alone as when it’s combined with surgery for some people with advanced kidney cancer.